Trump announces trade deal with EU following months of negotiations
NEW YORK - Henry Schein , Inc. (NASDAQ:HSIC) reported first quarter earnings that beat analyst expectations, but revenue fell short of estimates on Monday.
The company’s shares were down -1.36% in premarket trading following the release.
The healthcare products and services distributor posted adjusted earnings per share of $1.15, topping the consensus estimate of $1.12. However, revenue of $3.17 billion missed Wall Street’s forecast of $3.24 billion.
Total (EPA:TTEF) sales were essentially flat compared to the same quarter last year, declining 0.1% on a reported basis. Excluding foreign exchange impacts, sales grew 1.4% in constant currency.
"We are pleased with our first quarter financial results as well as the momentum we are seeing heading into the second quarter and remain confident in the fundamentals of our business," said Stanley M. Bergman, Chairman and CEO of Henry Schein.
The company maintained its full-year 2025 guidance, projecting adjusted earnings per share of $4.80 to $4.94. This outlook aligns with analysts’ average estimate of $4.84 per share. Henry Schein also reiterated expectations for total sales growth of 2% to 4% and mid-single digit growth in adjusted EBITDA for 2025.
Global dental sales declined 2.9% to $1.62 billion in the quarter, while medical sales rose 2.9% to $1.06 billion. The company’s technology and value-added services segment saw 2.9% growth to $162 million.
Despite the revenue miss, Henry Schein emphasized its progress on strategic initiatives. "We are advancing our BOLD+1 Strategic Plan, which has been refreshed for 2025 to 2027, with our team focused on growing the distribution business through increasing operational efficiency and enhancing customer experience," Bergman added.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.